Ila.Ax
ILA.AX is a biotechnology and medical research company operating in the healthcare sector, primarily generating revenue through pharmaceuticals and medical research activities.
Business. ILA.AX is a biotechnology and medical research company operating in the healthcare sector, primarily generating revenue through pharmaceuticals and medical research activities.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
ILA.AX is a biotechnology and medical research company operating in the healthcare sector, primarily generating revenue through pharmaceuticals and medical research activities.
ILA.AX has a highly liquid capital structure, as evidenced by a current ratio of 22.27, indicating that its current assets significantly exceed its current liabilities. The company is entirely equity-funded, with no long-term debt, and a debt-to-equity ratio of 0.0. However, the company is experiencing negative returns, with a return on equity of -54.78% and a return on assets of -52.32%, which are well below the typical performance metrics for the biotechnology and medical research industry.
The company's profitability is severely challenged, with a net loss of -3,920,140 AUD and an operating loss of -3,896,220 AUD in the latest reporting period. These figures suggest that the company is not currently generating sufficient revenue to cover its operating costs, let alone produce a profit. The operating cash flow is also negative at -2,768,370 AUD, indicating that the company is consuming cash rather than generating it from operations.
ILA.AX's revenue is not segmented by geographic region or business line in the available data, so it is not possible to assess the geographic or segment concentration of its revenue. However, the company's total revenue of 58,800 AUD is relatively small, which may suggest a niche or early-stage business model.
The company's growth trajectory is uncertain, as the latest financial data does not provide a clear indication of future revenue growth. Analyst estimates for the next reporting period suggest a mean revenue of 0.00 AUD and a mean EBIT of -6,500,000 AUD, which implies continued losses. The company's operating losses and negative cash flow from operations suggest that it may need to rely on external financing or asset sales to fund its operations in the near term.
ILA.AX is currently assessed as having low liquidity and low dilution risk, with no immediate filing-based liquidity or dilution flags detected. The company's equity base is substantial at 7,156,600 AUD, and it has no long-term debt, which reduces the risk of financial distress. However, the company's negative cash flow and operating losses may necessitate future equity or debt financing, which could lead to dilution for existing shareholders.
There are no recent events or filings disclosed in the available data that would indicate significant changes in the company's operations or financial position. The company's financial performance and risk profile remain largely unchanged from the latest available data.
- ILA.AX is a biotechnology and medical research company with a highly liquid capital structure but is currently experiencing significant operating and net losses.
- The company has no long-term debt and a debt-to-equity ratio of 0.0, indicating a conservative capital structure.
- ILA.AX's return on equity and return on assets are both negative, suggesting poor profitability and asset utilization.
- The company's operating cash flow is negative, indicating that it is consuming cash rather than generating it from operations.
- Analyst estimates suggest continued losses in the next reporting period, with no clear path to profitability.
- The company is assessed as having low liquidity and low dilution risk, but its financial position may require external financing in the near term.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Return On Assetsnet_income / total_assets
- ILA.AX Market data — financials · 2026-05-28
- Island Pharmaceuticals Ltd Market data — analyst estimates · 2026-05-28